# Efficacy and Safety of Lenvatinib as an Adjuvant Therapy for Hepatocellular Carcinoma

> **NCT04227808** · PHASE2 · UNKNOWN · sponsor: **Shanghai Zhongshan Hospital** · enrollment: 50 (estimated)

## Conditions studied

- Hepatocellular Carcinoma (HCC)

## Interventions

- **DRUG:** Lenvima 4 mg Oral Capsule

## Key facts

- **NCT ID:** NCT04227808
- **Lead sponsor:** Shanghai Zhongshan Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-12-12
- **Primary completion:** 2021-12-30
- **Final completion:** 2022-02-28
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2020-01-14

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04227808

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04227808, "Efficacy and Safety of Lenvatinib as an Adjuvant Therapy for Hepatocellular Carcinoma". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04227808. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*